Gujarat Themis Biosyn Acquires Sanofi’s Anti-TB Drug Portfolio for €158 Million
2 hours agoBusiness
32LENS
3 SourcesGujarat, India
TBNthebalanced.news

Gujarat Themis Biosyn Acquires Sanofi’s Anti-TB Drug Portfolio for €158 Million

Gujarat Themis Biosyn has signed an Asset Purchase Agreement with Sanofi to acquire a portfolio of 13 branded generic anti-tuberculosis and anti-infective products for approximately €158 million (around ₹1,738 crore). The portfolio, present in over 55 countries across Europe, the Middle East, and Africa, generated about €62 million in revenue in FY2025. The deal excludes manufacturing facilities and employees, enabling a capital-efficient expansion. The acquisition aims to strengthen Gujarat Themis Biosyn's global footprint and leverage its fermentation-based capabilities to enhance margins and supply integration.

Political Bias
0%100%0%
Sentiment
75%
AI analysis of 3 sources · Published under editorial oversight by The Balanced News
Analysed 24 Apr 2026· How this analysis is produced· Editorial standards· Corrections

AI Analysis

Political bias across 3 sources
● Left 0%● Center 100%● Right 0%

The articles primarily focus on the business and strategic aspects of the acquisition, presenting perspectives from company officials and market data without political framing. Coverage emphasizes corporate growth and market expansion, reflecting a neutral business-oriented viewpoint without partisan or ideological bias.

Sentiment — Positive (75/100)

The tone across the articles is generally positive, highlighting the acquisition as a strategic and financially beneficial move for Gujarat Themis Biosyn. The coverage underscores growth opportunities and market expansion, with no critical or negative sentiment evident.

How 3 sources covered this story

Each source's own headline, political lean, and sentiment — so you can see framing differences at a glance.

SourceTheir headlineBiasSentiment
mintGujarat-based pharma stock jumps over 15 despite stock market crash; here's why Stock Market NewsCenterPositive
businessstandardGujarat Themis Biosyn zooms 14 on acquiring Sanofi's TB drug portfolioCenterPositive
freepressjournalGujarat Themis Biosyn Acquires Sanofi Portfolio In 1,738 Crore Deal To Expand Global ReachCenterPositive

Coverage timeline

freepressjournal broke this story on 24 Apr, 05:36 am. Other outlets followed.

  1. 1
    freepressjournal24 Apr, 05:36 am
    Gujarat Themis Biosyn Acquires Sanofi Portfolio In 1,738 Crore Deal To Expand Global Reach
  2. 2
    businessstandard24 Apr, 07:23 am
    Gujarat Themis Biosyn zooms 14 on acquiring Sanofi's TB drug portfolio
  3. 3
    mint24 Apr, 07:47 am
    Gujarat-based pharma stock jumps over 15 despite stock market crash; here's why Stock Market News

Lens Score breakdown

32/100
Public interest0/100
Coverage gap100%

Well-covered story — coverage matches public importance.

Who's involved

Institutions and figures named across source coverage.

Corporate
Gujarat Themis BiosynSanofi

Story context

Category
Business
Location
Gujarat, India
Sources analysed
3
Last analysed
24 Apr 2026
Key entities
SanofiTuberculosisEuroGujaratInfectionEuropeMarketingMiddle EastAfricaJurassic ParkThemisIndian rupee